Brand Name

Metopirone

Generic Name
Metyrapone
View Brand Information
FDA approval date: January 25, 1962
Classification: Adrenal Steroid Synthesis Inhibitor
Form: Capsule

What is Metopirone (Metyrapone)?

Metopirone is indicated, in combination with other diagnostic tests, for the diagnosis of adrenal insufficiency in adult and pediatric patients. Metopirone is indicated, in combination with other diagnostic tests, for the diagnosis of adrenal insufficiency in adult and pediatric patients.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

Acute Consequences of Glucocorticoid Secretion in Overweight and Obese Individuals During Maximum Calorie Intake: a Double-blind, Randomized, Placebo-controlled, Cross-over Study
Acute Consequences of Glucocorticoid Secretion in Overweight and Obese Individuals During Maximum Calorie Intake: a Double-blind, Randomized, Placebo-controlled, Cross-over Study
Enrollment Status: Recruiting
Publish Date: April 16, 2025
Intervention Type: Drug
Study Phase: Not Applicable

Summary: The investigator aim to understand whether food-induced glucocorticoids influence fat mass in overweight and obese people. In a randomized, cross-over study, 23 overweight and obese volunteers will receive a block and replace therapy that mimics physiological glucocorticoid (GC) rhythm (metyrapone plus hydrocortisone) or placebo. Participants will undergo two identical overfeeding periods with eac...

A Multicentre, Open-label Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.
A Multicentre, Open-label Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.
Enrollment Status: Recruiting
Publish Date: April 02, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: This study is a national, multicenter, interventional, phase II clinical trial on the use of pembrolizumab in advanced adrenocortical carcinoma, with confirmed progression within 6 months, following EDP or EDP-M ( etoposide, doxorubicin, cisplatin- mitotan) chemotherapy. Adrenocortical carcinoma is a very rare entity with poor prognosis and limited therapeutic options. Only radical surgical treatm...

Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Subclinical/Mild Cushing's Syndrome
Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Subclinical/Mild Cushing's Syndrome
Enrollment Status: Recruiting
Publish Date: January 30, 2025
Intervention Type: Drug
Study Phase: Phase 4

Summary: Drug interventional, controlled, randomized open-label, parallel-group, multicenter study in patients with bilateral adrenal incidentalomas associated with subclinical Cushing's syndrome

View All Clinical Trials

Related Latest Advances

Effects of Metyrapone in Patients with Mild Hypercortisolism.
Effects of Metyrapone in Patients with Mild Hypercortisolism.
Journal: European journal of endocrinology
Published: September 15, 2025
Blood steroid hormone profile and clinical outcomes following switching from metyrapone to osilodrostat in patients with Cushing disease.
Blood steroid hormone profile and clinical outcomes following switching from metyrapone to osilodrostat in patients with Cushing disease.
Journal: Endocrine journal
Published: August 31, 2025
Adverse Event Profile Differences Between Metyrapone and Osilodrostat: A Pharmacovigilance Study of the FDA Adverse Event Reporting System.
Adverse Event Profile Differences Between Metyrapone and Osilodrostat: A Pharmacovigilance Study of the FDA Adverse Event Reporting System.
Journal: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
Published: August 18, 2025
View All Latest Advances

Brand Information

Metopirone (Metyrapone)
1INDICATIONS AND USAGE
Metopirone is indicated, in combination with other diagnostic tests, for the diagnosis of adrenal insufficiency in adult and pediatric patients.
2DOSAGE FORMS AND STRENGTHS
Capsules: Metopirone 250 mg soft gelatin, white to yellowish‑white, oblong, opaque, imprinted with "HRA" on one side in red ink.
3CONTRAINDICATIONS
Metopirone is contraindicated in patients with adrenal cortical insufficiency or hypersensitivity to Metopirone or to any of its excipients.
4ADVERSE REACTIONS
The following adverse reactions associated with the use of Metopirone were identified in clinical trials or postmarketing reports. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
  • Cardiovascular System:Hypotension
  • Gastrointestinal System:Nausea, vomiting, abdominal discomfort or pain
  • Central Nervous System:Headache, dizziness, sedation
  • Dermatologic System:Allergic rash
  • Hematologic System:Leukopenia, anemia, and/or thrombocytopenia
5OVERDOSAGE
Death occurred in a child after two doses of Metopirone 2 g.
6DESCRIPTION
Metopirone (metyrapone capsules) is an adrenal steroid synthesis inhibitor, available as 250‑mg capsules for oral administration. Its chemical name is 2‑methyl‑1, 2‑di‑3‑pyridyl‑1‑propanone, and its structural formula is
Chemical Structure
Metyrapone is a white to light amber, fine, crystalline powder, having a characteristic odor. It is sparingly soluble in water, and soluble in methanol and in chloroform. It forms water‑soluble salts with acids. Its molecular weight is 226.27.
Inactive Ingredients: Ethyl vanillin, gelatin, glycerol, macrogol 400, macrogol 4000, paramethoxy acetophenone, purified water, sodium ethyl parahydroxybenzoate, sodium propyl parahydroxybenzoate, titanium dioxide, + red ink (aluminum chloride hexahydrate, carminic acid, hypromellose, propylene glycol, sodium hydroxide).
7PATIENT COUNSELING INFORMATION
Advise patient to read the FDA-approved labeling (Patient Information).
Advise patient that Metopirone may induce acute adrenal insufficiency (nausea, vomiting, abdominal pain, hypotension)
Advise patient that Metopirone may cause dizziness and sedation. Advise patients not to drive or operate machinery until these effects have passed
8PRINCIPAL DISPLAY PANEL - 250 mg Bottle Carton
NDC 76336-455-18
Metopirone
18 capsules
HRA Pharma
PRINCIPAL DISPLAY PANEL - 250 mg Bottle Carton